Interaction between 1-Cys peroxiredoxin and ascorbate in the response to H2O2 exposure in Pseudomonas aeruginosa
- PMID: 40367862
- PMCID: PMC12141841
- DOI: 10.1016/j.redox.2025.103658
Interaction between 1-Cys peroxiredoxin and ascorbate in the response to H2O2 exposure in Pseudomonas aeruginosa
Abstract
Pseudomonas aeruginosa, a leading cause of hospital-acquired infections, triggers host defenses, including oxidant release by phagocytes. Targeting bacterial antioxidants could reduce pathogen infectivity. This study investigates LsfA, a 1-Cys peroxiredoxin (Prx), member of the Prx6 subfamily, involved in P. aeruginosa virulence. LsfA efficiently reduced various peroxides (106-107 M-1s-1), while exhibiting hyperoxidation resistance (khyperoxidation ∼102 M-1s-1). Despite its substrate oxidizing promiscuity, LsfA displayed specific reduction by ascorbate (2.2 × 103 M-1s-1). Moreover, elucidating the LsfA's crystallographic structures in the reduced and sulfinic/sulfonic acid states at 2.4 and 2.0 Å resolutions unveiled possible residues related to ascorbate binding. Small-angle X-ray scattering (SAXS) and size-exclusion chromatography (SEC) confirmed LsfA as a dimer regardless of its oxidative state. Microbiological assays, including a real-time analysis employing Hyper7, a genetically encoded probe, showed that ascorbate enhanced H2O2 removal in a LsfA-dependent manner. Hence, our integrated structural, biochemical, and microbiological analyses underscored the significance of the ascorbate-LsfA pathway in P. aeruginosa response to H2O2.
Keywords: 1-Cys peroxiredoxin; Ascorbate; H(2)O(2) response; LsfA; Pseudomonas aeruginosa, sulfenic acid.
Copyright © 2025. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Chatterjee M., et al. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int. J. Med. Microbiol. 2016;306:48–58. - PubMed
-
- Mesaros N., et al. Pseudomonas aeruginosa: resistance and therapeutic options at the dawn of the 2d millennium. Antibiotiques. 2007;9:189–198. - PubMed
-
- Yordanov D., Strateva T. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J. Med. Microbiol. 2009;58:1133–1148. - PubMed
-
- Harbarth S., et al. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET...
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
